Drug Profile
Ifebemtinib - InxMed
Alternative Names: BI 853520; IN-10018Latest Information Update: 28 Mar 2024
Price :
$50
*
At a glance
- Originator Boehringer Ingelheim
- Developer Boehringer Ingelheim; InxMed
- Class Antineoplastics; Small molecules
- Mechanism of Action Focal adhesion protein-tyrosine kinase inhibitors; PTK2 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I/II Breast cancer; Head and neck cancer; Malignant melanoma; Ovarian cancer; Pancreatic cancer; Small cell lung cancer; Solid tumours
- No development reported Uveal melanoma
Most Recent Events
- 28 Mar 2024 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Second-line therapy or greater) in Canada (PO)
- 28 Mar 2024 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Second-line therapy or greater) in Japan (PO)
- 28 Mar 2024 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Second-line therapy or greater) in Netherlands (PO)